Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects
a Single-center, One-arm, Open, and Fixed Sequences Study to Evaluate the Effects of Omeprazole on the Pharmacokinetics of Fluzoparib in Healthy Male Volunteers
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Listed as NCT04108676, this PHASE1 trial focuses on Advanced Solid Tumor and remains completed. Sponsored by Jiangsu HengRui Medicine Co., Ltd., it has been updated 6 times since 2019, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Sep 2022 — Jul 2024 [monthly]
Completed PHASE1
Status: Unknown Status → Completed
-
Oct 2021 — Sep 2022 [monthly]
Unknown Status PHASE1
Status: Active Not Recruiting → Unknown Status
-
Jan 2021 — Oct 2021 [monthly]
Active Not Recruiting PHASE1
▶ Show 1 earlier version
-
Oct 2019 — Jan 2021 [monthly]
Active Not Recruiting PHASE1
First recorded
Sep 2019
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Jiangsu HengRui Medicine Co., Ltd.
- The Third Xiangya Hospital of Central South University
For direct contact, visit the study record on ClinicalTrials.gov .